Condition (MeSH)
Hemangioma, Cavernous
ClinicalTrials.gov lists 19 trials for Hemangioma, Cavernous or a narrower condition beneath it. Recursion Pharmaceuticals Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 19 trials are tagged with Hemangioma, Cavernous itself; the rest are tagged with a narrower condition beneath it.
When did Hemangioma, Cavernous trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 5 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 19 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemangioma, Cavernous trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Not applicable | 2 |
| Observational | 9 |
How many Hemangioma, Cavernous trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 7 |
| Terminated | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemangioma, Cavernous trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Recursion Pharmaceuticals Inc. | 1 |
Which drugs are being tested for Hemangioma, Cavernous? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ATORVASTATIN | 1 |
| SIMVASTATIN | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Propranolol PO | 2 |
| REC-994 | 1 |
| Biocollection | 1 |
| Observational | 1 |
| Daratumumab SC | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemangioma, Cavernous trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Elevated creatine kinase (CK) | 1 | 1 |
| Fall | 1 | 1 |
Which publications cover Hemangioma, Cavernous? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). | Neurosurgery | 2021 | Yes |
| Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. | Nature communications | 2020 | Yes |
| Traumatic neuroma of the superficial peroneal nerve in a patient: a case report and review of the literature. | World journal of surgical oncology | 2016 | Yes |
| Intraoperative localization of subcortical brain lesions. | Acta neurochirurgica | 2008 | Yes |
| Blue rubber bleb nevus syndrome: case report and literature review. | Romanian journal of gastroenterology | 2004 | Yes |
Showing 5 of 13 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.